Clinical Trial Update: Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether adding Symbicort to Spiriva improves efficacy and tolerability versus Spiriva alone in patients with severe chronic obstructive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Spiriva (tiotropium)
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Status: COMPLETED | Results posted: 2014-08-27